CClinicalTrials.gg
Sign In
WithdrawnNCT01009944Updated Apr 9, 2021

Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study

An interventional study of Lisinopril, Atenolol in Hypertension, sponsored by Brigham and Women's Hospital. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-04-09.

Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Treatment

Why this study was withdrawn
Not funded.

From the registry’s dates

  • Registered 2 years 10 months after the study started (first participant enrolled Jan 2007, registered Nov 2009).
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to develop an approach to provide personalized medicine to individuals who have hypertension (high blood pressure). The investigators plan to use people's genetic characteristics (traits) to determine what medication they should use to lower their blood pressure most effectively. The investigators will give individuals one of two medications to treat hypertension (lisinopril or atenolol). The investigators believe that depending on the individuals genetic background one medication will work better in lowering their blood pressure.

02

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • High blood pressure
03

In context

Hypertension

6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.

Browse Hypertension studies →

Lead sponsor

Brigham and Women's Hospital is the lead sponsor of 1,236 studies on the registry; 224 are open to participants now.

Of its 116 completed or terminated interventional studies of FDA-regulated products, 64 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Male and female hypertensive participants who were previously studied in SCOR program.

Exclusion criteria

Exclusion Criteria:

  • Diabetes
  • Taking other medications beside thyroid or estrogen supplements.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Lisinopril, Atenolol

    Drug: Lisinopril, Atenolol

Interventions

  • DrugLisinopril, Atenolol

    once a day for 14 weeks

    Also known as: Tenormin (Atenolol), Prinivil, Zestril (Lisinopril)

06

What researchers measure

Primary outcomes

  1. One type of blood pressure medication will better treat individuals with certain genetic backgrounds.

    Time frame: 16 weeks

07

Study locations

1 site
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01009944
Lead sponsor
Brigham and Women's Hospital
Collaborators
University of Utah
Responsible party
Gordon H. Williams, MD (Chief, Cardiovascular Endocrinology Section, Brigham and Women's Hospital) — Principal investigator
First posted
Nov 9, 2009
Start date
Jan 2007
Primary completion
Mar 19, 2019
Completion
Mar 19, 2019
Last update
Apr 9, 2021

Study contacts

Gordon H. Williams, MD
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Hypertension→

Other studies from this sponsor

Brigham and Women's Hospital

Start the discussion